Clinical Trials Results - National Cancer Institute

Skip to content

NCI Home

Cancer Topics

Clinical Trials

Cancer Statistics

Research & Funding

News

About NCI


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 1469 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Supportive care, Treatment				Completed				18 and over				Pharmaceutical / Industry				20050100 NCT00352703


2.		Treatment of Acute Myeloblastic Leukemia in Younger Patients

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Biomarker/Laboratory analysis, Treatment				Closed				65 and under				Other				AML99<=65 años NCT00390715

Last Modified: 12/1/1998


3.		Phase II/III Randomized Study of Monoclonal Antibody HuM195 As Maintenance Therapy in Elderly Patients with Acute Myeloid Leukemia in Complete Remission Following Chemotherapy (Summary Last Modified 12/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				60 and over				Pharmaceutical / Industry				PDL-3-251 MSKCC-93131, NCI-V94-0469

Last Modified: 11/1/1997


4.		Phase II/III Pilot Treatment of Pediatric Non-B, Non-T ALL in First Marrow Relapse (SIMAL #8): Intensive Re-Induction and Reconsolidation Chemotherapy with Subsequent Myeloablative Chemoradiotherapy and Rescue with Either Allogeneic or In Vitro-Purged Autologous Marrow (Summary Last Modified 11/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				under 21 at relapse				NCI				POG-9410 POG-SIMAL-8, POG-9410


5.		Phase II/III cis-Platinum in 2-Drug and 3-Drug Combinations with VP-16 and DAVA for Advanced non-Oat Cell Carcinoma of the Lung

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				no age specified								MDA-DT-8075 NCI-D81-043-098


6.		Phase II/III Chemotherapy with CAMP (CTX/ADR/MTX/PCB) vs VP-16/DAVA/CACP vs VP-16/CACP vs DAVA/CACP for Stage III Metastatic non-Small Cell Bronchogenic Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				under 70								UCCRC-3248 NCI-D81-014-080


7.		Phase II/III Combination Chemotherapy with AMSA/AZC or AMSA/VP-16 for Acute Nonlymphocytic Leukemia Refractory to Standard Therapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				no age specified								NCI-D82-013-686


8.		Phase II/III Combination Chemotherapy with VP-16213/CTX/CACP in Patients with Stage II/III Testicular Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				over 15								NCI-D82-043-188 MDA-IM-8104


9.		Phase II/III Consolidation Chemotherapy with VP-16/AMSA/AZC Following Induction with DNM/ARA-C/TG for Adult Primary or Secondary Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 and over								NCI-D82-051-605


10.		Phase II/III Randomized Evaluation of VP-16 at Three Dosage Levels for Recurrent or Refractory Small Cell Carcinoma of the Lung

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				65 and under								SEG-LUN-81342R

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute